Recent news highlights Pulmonx’s narrowed Q2 losses, margin gains, and ongoing commercial momentum with the Zephyr Valve. The company reported Q2 2026 results showing revenue growth and improved operating metrics. Multiple news articles discuss Pulmonx’s position as a top biotech gainer and detail earnings call highlights.

• Pulmonx reported narrowed Q2 losses and margin gains in 2026, with Q2 revenue rising 15% year-over-year [N1][N3][N5].
• The company’s Q2 2026 earnings call emphasized commercial progress and operational improvements [N4].
• Pulmonx was noted among top biotech gainers in early August 2026, reflecting positive market attention [N1].
• Recent earnings transcripts and reports detail ongoing efforts to expand adoption and improve financial performance [N6][N7].
• The company’s commercial momentum is supported by increased hospital and physician adoption of the Zephyr Valve [N3][N4].

Pulmonx’s commercial progress with the Zephyr Valve, including increased hospital adoption and physician training, supports revenue growth potential. Narrowed losses and margin improvements reported in recent quarters indicate operational leverage. The company’s strong liquidity position provides runway to invest in sales, marketing, and product development. Positive coverage policies with major payors and ongoing clinical studies may enhance reimbursement and market acceptance. Expansion into new indications or geographies could broaden the addressable market. Continued innovation and competitive positioning may strengthen Pulmonx’s market presence.

Pulmonx faces significant risks from its dependence on a single product with limited indications. Adoption may be hindered by physician reluctance, reimbursement challenges, and hospital contracting difficulties. Safety risks and procedural complications could limit patient acceptance. The company’s history of net losses and need for additional capital raise concerns about financial sustainability. Regulatory delays or failures could impede product expansion. Competition from alternative therapies and emerging technologies may erode market share. Fluctuating operating results and uncertain market size add to execution risks.

Pulmonx’s moat is primarily based on its proprietary Zephyr Endobronchial Valve technology and its regulatory approvals for treatment of severe emphysema. The company’s early market entry and established relationships with pulmonologists and hospitals provide some competitive advantage. Its training programs and clinical data supporting the safety and efficacy of the Zephyr Valve contribute to physician adoption. However, the moat is limited by the company’s reliance on a single product with narrow indications, ongoing regulatory hurdles, and competition from alternative therapies and emerging technologies. The need for reimbursement coverage and hospital contracting also constrains market penetration. Pulmonx’s moat depends on continued innovation, regulatory success, and expanding clinical acceptance.

• Single Product Dependence: Pulmonx relies entirely on the Zephyr Endobronchial Valve for revenue, with no other therapeutic products currently approved for sale in the US. Failure to commercialize or expand indications could negatively impact the business [S1][S2].
• Limited Marketing and Sales Experience: The company has limited experience marketing and selling its solution, which may affect its ability to grow revenue and market share [S1][S2].
• Adoption and Reimbursement Challenges: Success depends on hospital, physician, and patient adoption, as well as obtaining and maintaining adequate reimbursement coverage. Lack of coverage or high out-of-pocket costs may hinder commercial success [S1][S2].
• Regulatory Risks: Pulmonx’s products are subject to extensive government regulation. Failure to obtain or maintain necessary approvals could adversely affect operations [S1][S2].
• Safety and Clinical Risks: Use of the Zephyr Valve involves risks such as pneumothorax and is contraindicated in certain patients, which may limit adoption and affect perception of safety and efficacy [S1][S2].
• Financial Sustainability: The company has a history of significant net losses and expects to continue incurring losses, requiring additional capital which may not be available on acceptable terms [S1][S2].
• Operational Fluctuations: Operating results may fluctuate significantly due to market adoption, regulatory developments, and competitive pressures, complicating financial planning [S1][S2].

• Pulmonx Corp is a medical device company focused on commercializing the Zephyr Endobronchial Valve (Zephyr Valve) as a treatment for severe emphysema and COPD [S1][S2].
• The company’s business currently depends entirely on the Zephyr Valve, which is approved for limited indications in the US and certain international markets [S1][S2].
• Pulmonx also sells and rents the Chartis System and related catheters, which are dependent on Zephyr Valve sales [S1][S2].
• The company began commercializing the Zephyr Valve in the US in 2018 and in Europe since 2003 [S1].
• Pulmonx’s revenue is primarily derived from sales of Zephyr Valves and delivery catheters [S1][S2].
• The company has a history of significant net losses, with a net loss of $10.08 million for Q2 2026 and an accumulated deficit of $545.3 million as of June 30, 2026 [S2].
• Pulmonx reported narrowed Q2 losses and margin gains in 2026, with Q2 revenue rising 15% year-over-year [N3][N5].
• The company’s liquidity as of June 30, 2026 includes $55.8 million in cash and equivalents, current assets of $88.1 million, current liabilities of $20.4 million, a current ratio of 4.32, and a cash ratio of 2.74 [S2].
• Pulmonx faces risks including reliance on a single product, limited marketing and sales experience, dependence on hospital and physician adoption, reimbursement challenges, and regulatory approvals [S1][S2].
• The company’s sales strategy focuses on building relationships with pulmonologists and educating other medical professionals to increase adoption [S1][S2].
• Use of the Zephyr Valve involves risks such as pneumothorax and is contraindicated in certain patients, which may limit adoption [S1][S2].
• Pulmonx’s operating results may fluctuate significantly, and the market size for its products is uncertain and may decline due to factors like reduced smoking rates [S1][S2].
• The company expects to continue incurring net losses and may require additional capital to finance operations [S1][S2].
• Pulmonx’s products and operations are subject to extensive government regulation in the US and abroad [S1][S2].
• The company’s Q2 2026 earnings call and reports highlight narrowed losses and revenue growth, indicating ongoing commercial momentum [N4][N5].
• Recent news coverage notes Pulmonx as a top biotech gainer with narrowed losses and margin gains in Q2 2026 [N1][N3].